s-1-(combination) and Tongue-Neoplasms

The prognosis of patients with locally advanced squamous cell carcinoma (SCC) of the tongue is poor. Postoperative chemoradiotherapy (CRT) improves locoregional control and survival in high-risk patients. We investigated the prognostic factors for clinical T4a tongue SCC, and elucidated whether postoperative CRT has a benefit for patients with poor prognosis in terms of survival.. We performed a retrospective analysis of 61 patients with stage T4a SCC of the tongue who underwent primary resection and neck dissection.. The median follow-up was 53.8 months. Multivariate analysis revealed a 4.26× relative risk of death for patients with the involvement of ≥5 regional lymph nodes (pN ≥5) compared with those with pN 0-4 (p = 0.002). In Kaplan-Meier analysis, patients with pN ≥5 who received CRT had longer overall survival rates than those who did not (hazard ratio = 0.31; p = 0.041).. pN ≥5 is the most powerful prognostic factor for clinical T4a SCC of the tongue. Postoperative CRT is recommended in patients with pN ≥5.

Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy, Adjuvant; Chemotherapy, Adjuvant; Cisplatin; Drug Combinations; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neck Dissection; Neoplasm Staging; Oxonic Acid; Patient Care Team; Postoperative Care; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Tegafur; Tongue Neoplasms

Amino-acid transporters are necessary for the tumour cell growth and survival, and have a crucial role in the development and invasiveness of cancer cells. But, it remains unclear about the prognostic significance of L-type amino-acid transporter 1 (LAT1), system ASC amino-acid transporter-2 (ASCT2), and xCT expression in patients with tongue cancer. We conducted the clinicopathological study to investigate the protein expression of these amino-acid transporters in tongue cancer.. Eighty-five patients with surgically resected tongue cancer were evaluated. Tumour sections were stained by immunohistochemistry for LAT1, ASCT2, xCT, 4F2hc/CD98hc (4F2hc), Ki-67, and microvessel density (MVD) determined by CD34, and p53.. L-type amino-acid transporter 1 and 4F2hc were highly expressed in 61% (52 out of 85) and 45% (38 out of 47), respectively. ASC amino-acid transporter-2 and xCT were positively expressed in 59% (50 out of 85) and 21% (18 out of 85), respectively. The expression of both LAT1 and ASCT2 was significantly associated with disease staging, lymph-node metastasis, lymphatic permeation, 4F2hc expression and cell proliferation (Ki-67). xCT expression indicated a significant association with advanced stage and tumour factor. By univariate analysis, disease staging, lymphatic permeation, vascular invasion, LAT1, ASCT2, 4F2hc, and Ki-67 had a significant relationship with overall survival. Multivariate analysis confirmed that LAT1 was an independent prognostic factor for predicting poor prognosis.. L-type amino-acid transporter 1 and ASCT2 can serve as a significant prognostic factor for predicting worse outcome after surgical treatment and may have an important role in the development and aggressiveness of tongue cancer.

Topics: Adult; Aged; Aged, 80 and over; Amino Acid Transport System ASC; Amino Acid Transport System y+; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Combinations; Female; Fusion Regulatory Protein 1, Heavy Chain; Humans; Kaplan-Meier Estimate; Ki-67 Antigen; Large Neutral Amino Acid-Transporter 1; Lymphatic Metastasis; Male; Middle Aged; Minor Histocompatibility Antigens; Neoplasm Proteins; Neoplasm Staging; Oxonic Acid; Prognosis; Taxoids; Tegafur; Tongue Neoplasms; Treatment Outcome; Tumor Suppressor Protein p53

Right partial glossectomy and supraomohyoid neck dissection were performed on a 65-year-old man with tongue squamous cell carcinoma. Postoperatively, S-1(80-120 mg/day)was administered as adjuvant chemotherapy. Six months later, an eruption accompanied by abdominal itching was recognized. Then leukoderma appeared on his face and both hands, continued to spread and it was diagnosed by dermatology as hypopigmentation. He has been doing well without any recurrence for 4 years, but the hypopigmentation remains unchanged.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Humans; Hypopigmentation; Male; Oxonic Acid; Remission Induction; Tegafur; Tongue Neoplasms

The development of reconstructive surgery and the use of free flaps have allowed for a larger dissection range even for advanced tongue cancer, resulting in an improvement of the prognosis. However, both the postoperative swallowing and masticatory function are still considered to have not yet reached a satisfactory level. Accordingly, our department has been administering concurrent chemoradiotherapy (CCRT) for advanced cancer to preserve the organ and the function; there are cases in which even comparatively small tumors are difficult to dissect due to the occurrence site. We have been treating these cases using CCRT as well. We herein report our results of 10 tongue cancer cases in which CCRT with S-1 and Nedaplatin (hereinafter, referred to as SN therapy) was administered in our department from April 2002 to October 2008. The complete response rate of the SN therapy was 60. 0% (6 of 10 examples). The 5-year disease-specific survival rates were 50. 0% for Stage II, 75. 0% for Stage III, and 75. 0% for Stage IV, respectively.

Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Combinations; Female; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxonic Acid; Survival Rate; Tegafur; Tongue Neoplasms

A 72-year-old man with tongue carcinoma complained of dyspnea on exertion 18 days after starting treatment with S-1. Chest radiograph and CT scan suggested diffuse interstitial lesions with ground glass opacity on both lungs. Bronchoalveolar lavage and transbronchial lung biopsy revealed moderate lymphocyte infiltration with granuloma. Drug lymphocyte stimulation test was positive against tegafur, one of the components of S-1. These findings were consistent with S-1-induced lung injury. Both his symptoms and the radiographic findings were resolved dramatically after high-dose corticosteroid therapy. Clinicians should be aware that S-1 has the potential to cause lung injury when it is included in chemotherapy.

Topics: Aged; Antimetabolites, Antineoplastic; Biopsy; Drug Combinations; Humans; Lung; Male; Oxonic Acid; Respiratory Distress Syndrome; Tegafur; Tongue Neoplasms

A 64-year-old male with primary squamous cell carcinoma of the tongue (T3N0M0) was treated with the novel fluoropyrimidine oral anticancer drug TS-1 and selective intra-arterial infusion of CDDP. His past history revealed pulmonary emphysema as a complication. Since his pulmonary function was reduced and it would have been difficult to perform surgery under general anesthesia, we started administration of TS-1 (100 mg/day) first and added selective arterial infusion of CDDP (5 mg/day) after one week of TS-1. On day 8 of TS-1 administration (day 2 of arterial infusion), the tumor had shrunk considerably, and on day 15 of TS-1 administration (day 9 of arterial infusion) the tumor had almost completely disappeared. Nausea and vomiting developed as adverse effects on day 20 of TS-1 administration (day 14 of arterial infusion), and administration of the anticancer drugs was stopped. Nutrition management and an antiemetic agent were started by intravenous drip infusion, and the adverse effects improved one week after administration was stopped. By the 5th week after the start of treatment, the tumor had disappeared macroscopically, and a CR had been achieved. Interstitial radiotherapy was performed as supplemental therapy, and as of this writing, September 3, 2002, 16 months after the start of treatment, the patient is being followed on an outpatient basis. His course has been favorable and recurrence-free. Although there were some slight adverse reactions, they were relatively mild, and since sufficient efficacy was observed, oral TS-1 plus selective intra-arterial CDDP therapy was concluded to be an effective method of treatment for patients with a past medical history making their general condition unfavorable.

Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Drug Administration Schedule; Drug Combinations; Humans; Infusions, Intra-Arterial; Male; Middle Aged; Nausea; Oxonic Acid; Pyridines; Remission Induction; Tegafur; Tongue Neoplasms; Vomiting, Anticipatory

A 75-year-old female with squamous cell carcinoma in the left margin of the tongue (T2N0M0) was referred to our hospital. She was treated with oral administration TS-1 80 mg/day as preoperative chemotherapy. After commencement of TS-1 administration, the tumor size was reduced at 1 week and had disappeared clinically at 4 weeks. Oral administration of TS-1 was done in 2 courses at the same dose. After two courses, histological examination reveled a complete disappearance of the cancer cells. No adverse effects were seen during the treatment period. She remains under oral administration of UFT for maintenance chemotherapy and there is no evidence of recurrence of the tumor.

Topics: Administration, Oral; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Administration Schedule; Drug Combinations; Female; Humans; Oxonic Acid; Pyridines; Remission Induction; Tegafur; Tongue Neoplasms; Uracil